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Cryptosporidicidal effects of two polyether ionophores (maduramicin and alborixin), a fluorinated 4-
quinolone (enrofloxacin), and three analogs of pentamidine were evaluated in a suckling mouse bioassay.
Treatment with all compounds except enrofloxacin and one of the pentamidine analogs [1,3-di(4-imidazolino-
phenoxy)propane] resulted in significant (P < 0.05) reductions in oocyst excretion.
Cryptosporidium spp. are small (2 to 6 ,um, depending on
the stage in the life cycle) protozoans that infect and develop
within the microvillous border of epithelial surfaces of
various organ systems of vertebrates (5). Several Cryptospo-
ridium species have been named; to date, only two species,
Cryptosporidium parvum and Cryptosporidium muris, are
known to parasitize mammals (19). C. parvum develops
principally in the small intestine and is the species respon-
sible for diarrhea in many animals including humans (19).
Prior to the discovery of the human immunodeficiency virus
and AIDS, parasites within the genus Cryptosporidium en-
gendered little more than academic interest. It is now known
that C. parvum may cause a transient gastrointestinal flu-like
illness in humans and that immunocompromised humans,
especially those with AIDS, can develop severe, protracted
cryptosporidial infections resulting in severe diarrhea and
perhaps death (3). C. parvum is now included in the AIDS-
defining complex of opportunistic agents. Although numer-
ous therapeutic and preventive modalities have been evalu-
ated, none have consistently eliminated the parasite or cured
clinical cryptosporidiosis in immunologically normal humans
and humans with AIDS (7).
Several assays have been proposed for evaluation of
cryptosporidicidal compounds in vivo and in vitro. Each
possesses inherent difficulties or deficiencies. Adult mice
(15) are less susceptible than suckling mice to cryptosporid-
ial infections and usually excrete too few oocysts to allow
their use as model hosts in chemotherapy studies. A model
utilizing chemically immunocompromised rats presents sim-
ilar problems regarding inconsistencies in excretion rates
and numbers of oocysts excreted (14). Infections in vitro and
in ovo also yield suboptimal numbers of parasites and are
unlikely to identify drugs requiring metabolism to active
products (4). At present, the suckling mouse assay appears
to provide reliable results with the fewest deficiencies or
difficulties (18).
The polyether ionophores are monovalent and divalent
cation-specific anticoccidial compounds effective in the pre-
vention and control of Eimeria-induced coccidiosis of cattle
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and poultry (2). The extremely high anticoccidial activity of
the ionophores has led to the discovery and development of
many such compounds.
The quinolones (e.g., decoquinate and buquinolate) are
effective as anticoccidial agents against Eimeria spp. and are
currently used as control agents in cattle or poultry (2). A
new generation of fluorinated 4-quinolones, with a broad
spectrum of antibacterial activity (e.g., enrofloxacin), are
currently under development (6). The cryptosporidicidal
activities of the fluorinated 4-quinolones are unknown.
The bisamidines (pentamidine and related compounds) are
a diverse group of agents with demonstrated parasiticidal
activity (2). Pentamidine and its analogs possess a broad
spectrum of activity against intracellular and extracellular
protozoa and against Pneumocystis carinii (1, 9, 17). When
pentamidine was administered parenterally to humans with
AIDS and concurrent cryptosporidiosis, no effect was ob-
served on either diarrhea or excretion of oocysts (16).
However, lack of efficacy could be attributed to the route of
administration. Parenteral dosing may not allow optimum
contact between Cryptosporidium stages and pentamidine.
Neither pentamidine nor its analogs have been evaluated
against Cryptosporidium species following oral administra-
tion.
In this report, we describe our murine model for the
evaluation of potential cryptosporidicidal compounds and
report the results of evaluations of the cryptosporidicidal
effects of two polyether ionophores (maduramicin and al-
borixin), a fluorinated 4-quinolone (enrofloxacin), and three
analogs of pentamidine (Fig. 1 and 2).
C. parvum (AUCp-1 isolate), originally obtained from a
naturally infected dairy calf, is maintained in the laboratories
of Byron L. Blagburn and David S. Lindsay by periodic
passage in male donor holstein calves. Oocysts are isolated
from feces and concentrated by flotation in Sheather's
sucrose solution (8) (specific gravity = 1.18), enumerated
with the aid of a hemacytometer, and stored in Hanks'
balanced salt solution at 4°C for not more than 6 weeks prior
to inoculation into suckling mice.
The polyether ionophores and enrofloxacin used in this
study were obtained as technical powders (maduramicin and
alborixin) or an injectable solution (enrofloxacin) from in-
dustrial sources as follows: maduramicin, American Cyana-
mid Corporation (Princeton, N.J.); alborixin, The Upjohn
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FIG. 1. Polyether ionophores and quinolones evaluated against C. parvum.
Company (Kalamazoo, Mich.); and enrofloxacin, Mobay
Animal Health (Shawnee Mission, Kans.). Pentamidine an-
alogs were synthesized in the laboratory of Richard R.
Tidwell, using the methods described previously (17). Im-
mediately prior to administration, compounds were mixed
with 90% (vol/vol) propylene glycol in deionized water or
deionized water alone (pentamidine analogs) at the appro-
priate concentrations to achieve the desired dosages when
administering a volume of 10 ,ul to a 3-g mouse (Tables 1 and
2). Control mice in each experiment received the same
vehicle without the test compound.
Evaluations were conducted as follows using our suckling
mouse bioassay. One-day-old Hsd:(ICR)BR outbred Swiss
Webster mice were obtained from commercial sources. Mice
were shipped to Auburn University as individual females
with litters. Upon arrival, pups were cross-fostered into
litters on the basis of body weight. This procedure created
litters of six 1-day-old mice with approximately equal mean
body weights. Litters were allocated to treatment and con-
trol groups, using a random number table. Treated mice
received test compounds once daily (see below) at dosages
recommended by the supplier (Tables 1 and 2). Mice in each
treatment and control group were treated using a Tracor
Atlas microdoser and syringe pump equipped with a tuber-
culin syringe and a 25-gauge, 1.59-cm-long needle, to which
a small piece of microbore tubing, (outer diameter, 0.076 cm;
inner diameter, 0.025 cm) was fitted (Tracor Atlas, Houston,
Tex.). Treatments with test compounds and infection with
C. parvum oocysts were performed by inserting the mi-
crobore tubing into the mouse's esophagus to a point ap-
proximately midway between the pharanyx and the stom-
ach. The syringe pump and microdoser were precalibrated
so that numerical increases on the microdoser corresponded
to known volumetric increases in solubilized compound or
vehicle. Mice were weighed prior to each treatment so that
an increased volume of compound could be given as the
weight of the mice increased (constant dose rate). Control
groups received the same amount of vehicle without the
candidate drug. Treatments were initiated when mice in each
group had achieved a weight of approximately 3.0 g. Mice in
each litter (treatment group) were treated daily with test
compound on day -1 (day prior to infection) through day 6.
Mice in each group were infected with approximately 105
oocysts of C. parvum on day 0, at least 2 h after treatment on
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TABLE 1. Activities of maduramicin, alborixin, and enrofloxacin
against experimentally induced C. parvum infections in
Hsd:(ICR)BR Swiss micea
Expt. no. and No. of Dosageb (mg/ No. (meanc ± SD) of
treatment group mice kg of body C. parvum oocystsweight) recovered/mouse
la
Maduramicin 39 1 29 ± 28d
Control 31 194 ± 143e
lb
Maduramicin 33 2.5 2 ± 2d
Control 29 87 ± 44e
2a
Alborixin 19 1.5 0.9 ± 1.1d
Control 24 122 ± 65e
2b
Alborixin 12 2.5 1.5 ± 2.5d
Control 15 161 ± 127e
3a
Enrofloxacin 24 3 171 ± 68d
Control 24 120 ± 83d
3b
Enrofloxacin 15 1 148 ± 103d
Control 10 109 ± 57d
a See Fig. 1 for chemical structures of the three compounds.
b Drugs were mixed in 90% propylene glycol-10% deionized water; control
mice received propylene glycol-water only.
c Means represent actual hemacytometer counts. Mean total oocysts recov-
ered from mice in each group can be approximated by multiplying by 25,000.
d,e Means within each experiment with different superscripts are signifi-
cantly different (P < 0.05).
that day. Mice in all treatment and control groups were
euthanatized by cervical dislocation on day 7. The portion of
the alimentary tract from the pylorus to the rectum was
removed from each mouse and separately placed in 10 ml of
2.5% (wt/vol) potassium dichromate solution. The alimen-
tary tract from each mouse was then ground by using a
Tekmar Tissuemizer (model SDI-1810; Tekmar Company,
Cincinnati, Ohio) to free oocysts. This was accomplished by
inserting the grinder rotor into the potassium dichromate
solution containing the alimentary tract and by slowly in-
creasing the rotor speed to a maximum rate of 24,000 rpm
over a period of approximately 15 s. This procedure was
repeated until a homogeneous mixture was achieved. Grind-
ing pulses did not exceed 15 s to avoid overheating the
specimen and possibly damaging oocysts. The numbers of
oocysts per milliliter of the 10-ml homogenates were deter-
mined with the aid of a hemacytometer. Oocysts were not
stained to enhance identification of oocysts prior to enumer-
ations. Mean numbers of oocysts recovered from treated and
control mice were compared by using the nonparametric
Wilcoxon Mann-Whitney test. A probability level of P <
0.05 was considered significant.
Adverse reactions resulting from treatment with the test
compounds were not observed. Daily weight gains for mice
treated with each test compound were similar to mice in the
control groups (detailed data not presented). Of the six
compounds evaluated, four significantly reduced the num-
bers of oocysts recovered from treated mice (Tables 1 and
2). Excellent efficacy was observed for the polyethers ma-
duramicin and alborixin (Table 1). Neither of these com-
TABLE 2. Activities of pentamidine analogs against
experimentally induced C. parvum infections
in Hsd:(ICR)BR Swiss micea
Expt. no. and No. of Dosageb No. (meanc + SD) of
treatment group mice (mg/kg) C parvum oocystsrecovered/mouse
4
Compound 1 19 2.8 4.5 ± 2.9d
Control 19 49.8 ± 47e
5
Compound 2 18 11.3 13.8 ± 11.5d
Control 14 10.3 ± 7.3d
6
Compound 3 32 11.3 28.6 ± 37.7d
Control 24 69.3 ± 71.7e
a See Fig. 2 for chemical structures of compounds 1 to 3.
b Drugs were mixed with deionized water; control mice received deionized
water only.
c Means represent actual hemacytometer counts. Mean total oocysts recov-
ered from mice in each group can be approximated by multiplying by 25,000.
d.e Means in each experiment with different superscripts are significantly
different.
pounds have been evaluated against C. parvum previously.
Studies with other polyethers in both in vivo and in vitro
assays have yielded variable results (11, 13). For example,
lasalocid appeared to have activity against C. parvum, but
this activity was observed only at a dosage that was toxic to
infected calves (12). Monensin reduced development of C.
parvum in cell cultures by more than 90% compared with
that of controls (11) but had little apparent activity in vivo
(12, 18). Our results indicate the need to further evaluate
alborixin and maduramicin against C. parvum. It would be
especially interesting to examine the effects of these com-
pounds in a clinical model of cryptosporidiosis.
Among the pentamidine analogs, compounds 1 and 3
demonstrated activity at the dosages tested (Table 2). These
results are noteworthy because they demonstrate the activ-
ity of certain pentamidine analogs against C. parvum and
imply an even broader spectrum of activity for these com-
pounds than originally indicated (1, 9, 17). Their broad
spectrum of activity is also supported by the demonstration
of activity of certain pentamidine analogs against Toxo-
plasma gondii in cell cultures (10). Numerous additional
analogs of pentamidine have been synthesized and are
available from Richard Tidwell's laboratory. Additional de-
tailed structure-activity studies are needed to identify those
compounds with maximum efficacy against C. parvum and
minimum host toxicity.
It is important to note that the evaluation regimens used in
these experiments were prophylactic, because test com-
pounds were administered to mice prior to infection with C.
parvum. Further evaluations of these compounds utilizing a
therapeutic regimen are desirable.
This study was supported by grants AmFAR 000501 to B.L.B.
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